Share This Article:

Clinical characteristics and risk factors of 27 liver failure patients complicated by invasive fungal infections

Abstract Full-Text HTML Download Download as PDF (Size:69KB) PP. 39-42
DOI: 10.4236/health.2011.31008    3,913 Downloads   7,080 Views   Citations

ABSTRACT

To investigate the clinical feature, risk factors and outcome of treatment in patients with liver failure complicated by invasive fungal infections. Retro-spective analysis of the clinical data and related factors of 27 patients with liver failure com-plicated by invasive fungal infections was per-formed. These patients were admitted from January 2007 to August 2009 in our department. Among them, Candida albicans accounted for 17cases (54.84%), albicans tropicals for 4 cases (12.90%). Fungal infection in respiratory tract and alimentary tract accounted for 58.06% and 11% respectively. 81.25% of them had fever fluctuating from 37.4oC to 40oC. 81.25% had elevated white blood cell counts .All had the usage of broad-spectrum of antibiotics, whereas some of them used corticosteroids and had invasive medical manipulation for the treatment. Most patients deteriorated after invasive fungal infections. 21 cases accepted with the treatment of antifungal drugs and mortality rate was 63.00%. It was found that the invasive fungal infection possibility of patients with liver failure significantly increased. To prevent the occurrence of invasive fungal infection, promptly early treatment of liver failure, proper use of antibiotics, cautious use or disuse of corticosteroids, reduction of invasive medical manipulation should be well done. Early detection and treatment of fungal infection are vital to decrease in mortality rate.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Jiang, L. , Li, J. , Han, Y. , Liu, Y. , Yan, Y. , Chen, N. , Dong, L. , Zhou, D. and Wang, R. (2011) Clinical characteristics and risk factors of 27 liver failure patients complicated by invasive fungal infections. Health, 3, 39-42. doi: 10.4236/health.2011.31008.

References

[1] Zhou, H.H., De, M.T., Guo, Z.L., et al. (2010) Clinical characteristics and therapeutic analysis of invasive fungal infection in chronic severe hepatitis patients. Medical Science, 35, 537-542.
[2] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association (2006) Diagnostic and treatment guidelines for liver failure. Journal of Clinical Hepatology, 9, 321-324.
[3] Richardson, I.M.D. and Jones, B.L. (2003) Therapeutic guidelines in systemic fungal infections. 3rd Edition, Current Medical Literature, 19-20.
[4] Critical Care Medicine Branch of the Chinese Medical Association (2007) Diagnosis and treatment guidelines of patients with severe invasive fungal infections. Chinese Journal of Internal Medicine, 46, 960-966.
[5] Dong, C.H., Wei, J., Zhi, H., et al. (2005) Infection and resistance of fungus. Chinese Journal of Nosocomiology, 15, 345-347.
[6] Julie, P. and William, M.L. (2005) The management of acute liver failure. Hepatology, 41, 1179-1196. doi:10.1002/hep.20703
[7] Zhang, X.H., Zhang, G.H., Man, C.J., et al. (2004) Clinical study on the severe hepatitis with nosocomial fungal infections and risk factors. Chinese Journal of Hepatology, 12, 389-391.
[8] Min, X., Qiang, C. and Qian, C.F. (2007) Clinical analysis of 186 severe hepatitis and cirrhosis patients with nosocomial fungal infections. Journal of Clinical Hepatology, 10, 24-27.
[9] Qi, F.X., Mei, L., Bing, L., et al. (2004) Risk factors of fungal colonization in patients with chronic liver disease: a prospective study. Chinese Journal of Nosocomiology, 14, 1344-1346.
[10] Segal, B.H., Amyroudis, N.G., Battiwalla, M., et al. (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad- spectrum antifungal agents and diagnostic adjuncts. Clinical Infective Disease, 44, 402-409. doi:10.1086/510677
[11] Rex, J.H. and Sobel, J.D. (2001) Prophylactic antifungal therapy in the intensive care unit. Clinical Infective Disease, 32, 1191-1200. doi:10.1086/319763
[12] Pfaller, M.A., Jones, R.N., Messer, S.A., et al. (1998) National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagnostic Microbiology and Infectious Disease, 31, 327-332. doi:10.1016/S0732-8893(97)00240-X
[13] Vehreschild, J.J., Bohme, A., Reichert, D., et al. (2008) Treatment of invasive fungal infections in clinical practice: A multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. International Journal of Hematology, 87, 126-131. doi:10.1007/s12185-008-0045-z
[14] Ying, J.W. (2008) Liver failure: Definitions, diagnosis and treatment. Journal of Clinical Hepatology, 16, 725- 727.
[15] Ju, P.D. and Chun, H.L., et al. (2007) Invasive diagnosis and treatment of fungal infections. Chinese Journal of Infection Control, 6, 359-364.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.